This article stated that: “Clinicians are looking at tackling that challenge by combining 'irreversible' EGFR inhibitors, such as Exelixis's XL647, with agents that inhibit another kinase, MET, such as XL184, a multitargeted kinase inhibitor also developed by Exelixis.”
There is an error in this sentence as Exelixis's EGFR inhibitor XL647 is in fact a reversible EGFR inhibitor. The correct version is: “Clinicians are looking at tackling that challenge by combining EGFR inhibitors, such as Exelixis's XL647, with agents that inhibit another kinase, MET, such as XL184, a multitargeted kinase inhibitor also developed by Exelixis.”
Additional information
The online version of the original article can be found at 10.1038/nrd2633
Rights and permissions
About this article
Cite this article
Opar, A. Erratum: ASCO presentations highlight value of cancer biomarkers. Nat Rev Drug Discov 7, 666 (2008). https://doi.org/10.1038/nrd2655
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd2655
